2024-2032 年按疫苗類型（肌肉內、鼻內、皮內）、市場類型（公共、私人）和地區分類的 H1N1 疫苗市場報告

2023年全球H1N1疫苗市場規模達37億美元。展望未來， IMARC Group預計到2032年市場規模將達到55億美元，2024-2032年複合年成長率（CAGR）為4.2%。日益成長的醫療保健問題、顯著的醫療進步、改善的醫療保健系統以及人們對 H1N1 疫苗重要性的認知不斷提高是推動市場的一些主要因素。

H1N1 疫苗，也稱為甲型流感 (H1N1) 疫苗，旨在提供對 H1N1 流感病毒株的保護。這種病毒株通常被稱為“豬流感”，在 2009 年引起了全球大流行。H1N1 疫苗含有去活化或弱化形式的病毒或其成分，促使免疫系統產生針對 H1N1 株的抗體。這些疫苗有助於預防感染並減輕病毒的傳播。它們通常包含在季節性流感疫苗配方中，以提供針對 H1N1 以及其他流行流感病毒株的免疫力。

流感大流行的持續威脅凸顯了有效疫苗預防 H1N1 病毒傳播的重要性，這是推動全球 H1N1 疫苗市場成長的關鍵因素之一。高傳播率和嚴重疾病的可能性推動了疫苗的需求，以保障公眾健康。人們對疫苗接種益處的認知不斷增強，以及政府促進免疫計畫的措施擴大了疫苗的採用，這進一步促進了市場的成長。公共衛生運動和教育工作也有助於提高疫苗接種率。此外，全球人口的相互聯繫加劇了預防措施的必要性。國際旅行和貿易促進了傳染病的快速傳播，因此需要強力的疫苗接種策略。此外，製藥公司、研究機構和衛生組織之間的合作推動創新並確保及時開發疫苗。監管支持和簡化的核准流程鼓勵對疫苗研究和生產的投資，這為全球市場創造了積極的前景。

H1N1 疫苗市場趨勢/促進因素：

加強大流行防範

未來疫情的威脅日益嚴重，促使政府、醫療機構和個人優先考慮疫苗接種作為預防措施，這推動了市場的成長。減少疾病傳播和保護弱勢群體的需求日益成長，推動了對 H1N1 疫苗的需求。再加上各國政府改善醫療基礎設施和增加醫療預算，都促進了市場的成長。

不斷增加的公共衛生舉措

世界各國政府和衛生當局擴大發起公共衛生運動，以促進疫苗接種並提高人們對影響市場成長的 H1N1 疫苗益處的認知。這些措施的重點是教育大眾、消除誤解並鼓勵積極接種疫苗，以確保廣泛預防病毒。這些活動有助於提高疫苗接種率並提高社區免疫力。各國政府也致力於改善公共醫療設施，使最偏遠的地區和邊緣化群體也能獲得這些設施，也促進了疫苗的接種。

全球旅行和互聯互通的成長

國際旅行和互聯互通的增加促進了 H1N1 等傳染病的快速傳播，這進一步推動了對 H1N1 疫苗的需求。全球人口的相互連結強調了人口層面的免疫力對於遏制傳播的重要性。 H1N1 疫苗為旅客提供保護並降低輸入和隨後傳播的風險，在減少跨境爆發的可能性方面發揮著至關重要的作用。

目錄

第1章：前言

第 2 章：範圍與方法

• 研究目的
• 利害關係人
• 資料來源
  • 主要資源
  • 二手資料
• 市場預測
  • 自下而上的方法
  • 自上而下的方法
• 預測方法

第 3 章：執行摘要

第 4 章：簡介

• 概述
• 主要行業趨勢

第 5 章：全球 H1N1 疫苗市場

• 市場概況
• 市場業績
• COVID-19 的影響
• 細分：依疫苗類型
• 細分：依市場類型
• 重點品牌分析
• 細分：按地區
• 市場預測

第 6 章：市場區隔：依疫苗類型

• 肌肉注射
  • 市場走向
  • 市場預測
• 鼻內
  • 市場走向
  • 市場預測
• 皮內
  • 市場走向
  • 市場預測

第 7 章：市場區隔：按類型

• 民眾
  • 市場走向
  • 市場預測
• 私人的
  • 市場走向
  • 市場預測

第 8 章：市場區隔：按地區

• 北美洲
  • 市場走向
  • 市場預測
• 歐洲
  • 市場走向
  • 市場預測
• 亞太地區
  • 市場走向
  • 市場預測
• 中東和非洲
  • 市場走向
  • 市場預測
• 拉丁美洲
  • 市場走向
  • 市場預測

第 9 章：重點品牌分析

• 阿格里帕爾
• 菲亞里克斯
• 流感基因
• 流感疫苗
• 納索瓦茨
• 維克斯握把
• 其他

第 10 章：SWOT 分析

• 概述
• 優勢
• 弱點
• 機會
• 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

• 概述
• 買家的議價能力
• 供應商的議價能力
• 競爭程度
• 新進入者的威脅
• 替代品的威脅

第 13 章：價格分析

• 價格指標
• 價格結構
• 利潤分析

第 14 章：產業發展

• 管道和新產品發布
• 併購及合作

第15章：競爭格局

• 市場結構
• 關鍵參與者
• 關鍵參與者簡介
  • Abbott Laboratories
  • AstraZeneca plc
  • CPL Biologicals Pvt. Ltd
  • CSL Limited
  • Zoetis Inc.

Abstract

The global H1N1 vaccines market size reached US$ 3.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4.2% during 2024-2032. The increasing healthcare concerns, significant medical advancements, improving healthcare systems, and rising awareness about the importance of H1N1 vaccines are some of the major factors propelling the market.

H1N1 vaccines, also known as influenza A (H1N1) vaccines, are designed to provide protection against the H1N1 strain of the influenza virus. This strain, commonly referred to as "swine flu," caused a global pandemic in 2009. H1N1 vaccines contain inactivated or weakened forms of the virus or its components, prompting the immune system to produce antibodies against the H1N1 strain. These vaccines help prevent infection and mitigate the spread of the virus. They are typically included in seasonal flu vaccine formulations to offer immunity against H1N1 along with other prevalent influenza strains.

The ongoing threat of influenza pandemics underscores the importance of effective vaccines to prevent the spread of the H1N1 virus which represents one of the key factors driving the growth of the H1N1 vaccines market across the globe. High transmission rates and the potential for severe illness drive the demand for vaccines to safeguard public health. The increasing awareness about vaccination benefits and government initiatives to promote immunization programs amplify vaccine adoption which is further contributing to the market growth. Public health campaigns and educational efforts also contribute to higher vaccination rates. Additionally, the global interconnectedness of populations intensifies the need for preventive measures. International travel and trade facilitate the rapid spread of infectious diseases, necessitating robust vaccination strategies. Furthermore, collaborations between pharmaceutical companies, research institutions, and health organizations drive innovation and ensure timely vaccine development. Regulatory support and streamlined approval processes encourage investment in vaccine research and production which is creating a positive outlook for the market across the globe.

H1N1 Vaccines Market Trends/Drivers:

Rise in pandemic preparedness

The rising threat of future pandemics drives governments, healthcare organizations, and individuals to prioritize vaccination as a preventive measure, which is driving the growth of the market. The increasing need to minimize disease transmission and protect vulnerable populations is fueling the demand for H1N1 vaccines. This, along with improving healthcare infrastructure and increasing healthcare budgets by governments of various nations is contributing to the market growth.

Rising public health initiatives

Governments and health authorities worldwide are increasingly launching public health campaigns to promote vaccination and raise awareness about the benefits of H1N1 vaccines which is influencing the market growth. These initiatives focus on educating the public, dispelling myths, and encouraging proactive vaccination to ensure widespread protection against the virus. These campaigns contribute to higher vaccine uptake rates and improved community immunity. Governments of various nations are also focused on improving public healthcare facilities, making them accessible to even the remotest regions and to the marginalized sections, which is facilitating the uptake of the vaccines.

Rise in global travel and connectivity

Increased international travel and connectivity facilitate the rapid spread of infectious diseases like H1N1 which is further propelling the demand for H1N1 vaccines. The interconnectedness of global populations emphasizes the importance of population-level immunity to curb transmission. H1N1 vaccines play a vital role in reducing the potential for cross-border outbreaks by offering protection to travelers and reducing the risk of importation and subsequent transmission.

H1N1 Vaccines Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global H1N1 vaccines market report, along with forecasts at the global and regional levels from 2024-2032. Our report has categorized the market based on vaccine type, key brands and market type.

Breakup by Vaccine Type:

Intramuscular

Intranasal

Intradermal

The report has provided a detailed breakup and analysis of the market based on the vaccine type. This includes intramuscular, intranasal, and intradermal. According to the report, intramuscular represented the largest segment.

Intramuscular vaccines hold a proven track record of eliciting strong and durable immune responses. The muscle tissue provides an optimal environment for antigen presentation, which leads to effective immune activation and antibody production. This enhances the vaccine's ability to confer protection against H1N1 and other influenza strains. Intramuscular injections are a well-established and familiar method in healthcare settings. Healthcare professionals are experienced in administering vaccines via this route, ensuring accurate dosing and proper delivery. The IM route is suitable for a wide range of age groups, from children to adults. This universality makes IM-administered H1N1 vaccines versatile and applicable in mass vaccination campaigns. Intramuscular injections are commonly associated with vaccination, contributing to public acceptance. People are accustomed to receiving vaccines in this manner, leading to fewer barriers and higher compliance rates.

Breakup by Market Type:

Public

Private

A detailed breakup and analysis of the market based on the market type has also been provided in the report. This includes public and private. According to the report, public accounted for the largest market share.

H1N1 vaccines serve crucial roles in public health by providing protection against the H1N1 strain of influenza virus. They help prevent widespread outbreaks by building population immunity, reducing the virus's transmission potential. This safeguards vulnerable individuals, such as the elderly, young children, and those with compromised immune systems. H1N1 vaccines minimize illness severity and related complications, reducing hospitalizations, medical costs, and the burden on healthcare systems. By preventing severe cases, vaccines contribute to overall public health and well-being. The widespread H1N1 vaccination efforts contribute to community immunity or herd immunity, indirectly protecting those who cannot be vaccinated due to medical reasons. This collaborative defense limits the virus's spread within the population. Furthermore, H1N1 vaccines play a pivotal role in pandemic preparedness, as they form the foundation for rapid response to emerging influenza strains with pandemic potential.

Breakup by Region:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

The report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the report, North America accounted for the largest market share.

In North America, the H1N1 vaccines market is driven by factors, including proactive public health initiatives, well-established vaccination programs, and a strong healthcare infrastructure. The memory of past outbreaks and pandemics, such as the 2009 H1N1 pandemic, has heightened awareness about the importance of vaccination. Robust healthcare systems, accessible medical facilities, and high levels of health literacy contribute to a culture of vaccination. Additionally, government support, regulatory frameworks, and public-private partnerships facilitate timely vaccine development, distribution, and administration. These factors collectively promote the demand for H1N1 vaccines, ensuring preparedness and protection against influenza outbreaks in North America.

Competitive Landscape:

Key players in the H1N1 vaccines market are actively engaged in several strategic initiatives to address the demand for effective vaccines and ensure public health preparedness. These companies focus on continuous research and development (R&D) to create vaccines with enhanced immunogenicity and broader coverage against H1N1 and related strains. Collaborations with research institutions and health authorities enable them to stay informed about evolving virus strains and pandemic potential. Moreover, key players invest in production scalability and efficiency to meet demand during outbreaks. They work closely with regulatory agencies to ensure vaccine safety, efficacy, and timely approvals. In addition, these companies engage in public health advocacy, promoting vaccination through education and awareness campaigns. Furthermore, collaborations with global health organizations, governments, and non-profit entities ensure equitable vaccine distribution, especially in regions with limited access to healthcare. By prioritizing innovation, safety, and accessibility, key players contribute to effective disease prevention and control in the H1N1 vaccines market.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbott Laboratories

AstraZeneca plc

CPL Biologicals Pvt. Ltd

CSL Limited

Zoetis Inc.

Recent Developments:

In February 2023, the World Health Organization (WHO) announced the recommendations for the viral composition of influenza vaccines for the 2023-2024 influenza season in the northern hemisphere. The announcement was made at an information session at the end of a 4-day meeting on the Composition of Influenza Virus Vaccines, a meeting that is held twice annually.

In February 2023, the FDA approved these vaccines as a strain change to each manufacturer's seasonal influenza vaccine. There is considerable experience with seasonal influenza vaccine development and production and influenza vaccines produced by this technology have a long and successful track record of safety and effectiveness in the United States. The Influenza A (H1N1) 2009 Monovalent vaccines will undergo the usual testing and lot release procedures that are in place for seasonal influenza vaccines.

In January 2022, with new vaccine targets and more powerful delivery platforms, researchers are making inroads toward an influenza vaccine that could offer better, longer-lasting protection.

In February 2020, Abbott India announced the launch of an inactivated vaccine in India against four strains of influenza virus.

Key Questions Answered in This Report

• 1. What was the size of the global H1N1 vaccines market in 2023?
• 2. What is the expected growth rate of the global H1N1 vaccines market during 2024-2032?
• 3. What are the key factors driving the global H1N1 vaccines market?
• 4. What has been the impact of COVID-19 on the global H1N1 vaccines market?
• 5. What is the breakup of the global H1N1 vaccines market based on the vaccine type?
• 6. What is the breakup of the global H1N1 vaccines market based on the market type?
• 7. What are the key regions in the global H1N1 vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global H1N1 Vaccines Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Breakup by Vaccines Type
• 5.5 Breakup by Market Type
• 5.6 Analysis of Key Brands
• 5.7 Breakup by Region
• 5.8 Market Forecast

6 Market Breakup by Vaccines Type

• 6.1 Intramuscular
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Intranasal
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Intradermal
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Type

• 7.1 Public
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Private
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Europe
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Asia Pacific
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Middle East and Africa
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Latin America
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Analysis of Key Brand

• 9.1 Agripal
• 9.2 Fiuarix
• 9.3 Influgen
• 9.4 Influvac
• 9.5 Nasovac
• 9.6 Vaxigrip
• 9.7 Others

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

• 13.1 Price Indicators
• 13.2 Price Structure
• 13.3 Margin Analysis

14 Industry Developments

• 14.1 Pipeline and New Product Launches
• 14.2 Mergers & Acquisitions and Partnerships

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 AstraZeneca plc
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 CPL Biologicals Pvt. Ltd
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 CSL Limited
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Zoetis Inc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis

List of Figures

• Figure 1: Global: H1N1 Vaccines Market: Major Drivers and Challenges
• Figure 2: Global: H1N1 Vaccines Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: H1N1 Vaccines Market: Breakup by Vaccines Type (in %), 2023
• Figure 4: Global: H1N1 Vaccines Market: Breakup by Type (in %), 2023
• Figure 5: Global: H1N1 Vaccines Market: Breakup by Region (in %), 2023
• Figure 6: Global: H1N1 Vaccines Industry: SWOT Analysis
• Figure 7: Global: H1N1 Vaccines Industry: Value Chain Analysis
• Figure 8: Global: H1N1 Vaccines Industry: Porter's Five Forces Analysis
• Figure 9: Global: H1N1 Vaccines Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 10: Global: H1N1 Vaccines (Intramuscular) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 11: Global: H1N1 Vaccines (Intramuscular) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 12: Global: H1N1 Vaccines (Intranasal) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 13: Global: H1N1 Vaccines (Intranasal) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 14: Global: H1N1 Vaccines (Intradermal) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 15: Global: H1N1 Vaccines (Intradermal) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 16: Global: H1N1 Vaccines (Public) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 17: Global: H1N1 Vaccines (Public) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 18: Global: H1N1 Vaccines (Private) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 19: Global: H1N1 Vaccines (Private) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 20: North America: H1N1 Vaccines Market: Sales Value (in Million US$), 2018 & 2023
• Figure 21: North America: H1N1 Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 22: Europe: H1N1 Vaccines Market: Sales Value (in Million US$), 2018 & 2023
• Figure 23: Europe: H1N1 Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 24: Asia Pacific: H1N1 Vaccines Market: Sales Value (in Million US$), 2018 & 2023
• Figure 25: Asia Pacific: H1N1 Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 26: Middle East and Africa: H1N1 Vaccines Market: Sales Value (in Million US$), 2018 & 2023
• Figure 27: Middle East and Africa: H1N1 Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 28: Latin America: H1N1 Vaccines Market: Sales Value (in Million US$), 2018 & 2023
• Figure 29: Latin America: H1N1 Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

• Table 1: Global: H1N1 Vaccines Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: H1N1 Vaccines Market Forecast: Breakup by Vaccines Type (in Million US$), 2024-2032
• Table 3: Global: H1N1 Vaccines Market Forecast: Breakup by Type (in Million US$), 2024-2032
• Table 4: Global: H1N1 Vaccines Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 5: Global: H1N1 Vaccines Market Structure
• Table 6: Global: H1N1 Vaccines Market: Key Players